Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

1.300 -0.020 (-1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
From Longeveron
Via GlobeNewswire
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
From Longeveron
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Earnings Scheduled For November 12, 2024
Via Benzinga
A Look Ahead: Longeveron's Earnings Forecast
Via Benzinga
Earnings Scheduled For February 28, 2025
Via Benzinga
Peeling Back The Layers: Exploring Longeveron Through Analyst Insights
Via Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present ‘Important’ Lomecel-B(TM) Data at the 17th Clinical Trials on Alzheimer’s Disease Conference
Via Investor Brand Network
Beyond The Numbers: 4 Analysts Discuss Longeveron Stock
Via Benzinga
Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates
The good news on Lomecel-B comes at an opportune time for Longeveron and LGVN stock -- it could attract a buyer. 
Via InvestorPlace
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) CEO to Participate in Fireside Cat at UBS Virtual Organ Restoration and Cell Therapy Day
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHS
Via Investor Brand Network
(LGVN) - Analyzing Longeveron's Short Interest
Via Benzinga
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
Via Investor Brand Network
LGVN Stock Earnings: Longeveron Misses EPS, Beats Revenue for Q2 2024
LGVN stock results show that Longeveron missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call
Via Investor Brand Network
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others. 
Via Benzinga
The Top 3 Small-Cap Stocks to Buy Now: Summer 2024
Small-cap stocks are on the rise once again as the Federal Reserve ponders cutting interest rates, which has held back the sector. 
Via InvestorPlace
Topics Economy
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report. 
Via InvestorPlace
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Lomecel-B(TM) Study Results Presented at the Alzheimer’s Association International Conference
Via Investor Brand Network
Why Is Alzheimer's-Focused Longeveron Stock Trading Higher On Monday?
Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's safety and efficacy in treating Alzheimer's, demonstrating slowed disease... 
Via Benzinga
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning! 
Via InvestorPlace
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.